Biocartis: SeptiCyte Rapid

Biocartis has launched its CE-marked SeptiCyte Rapid assay for its Idylla platform. The test distinguishes sepsis from non-infectious systemic inflammation in patients suspected with sepsis and provides results within an hour, the firm said.